Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Core Insights - Abbott presented new clinical data at the AF Symposium demonstrating the safety and efficacy of its ablation catheters for treating atrial fibrillation (AFib) [1] Group 1: Volt PFA System - The Volt Pulsed Field Ablation (PFA) System achieved an industry-leading success rate of 84.2% for freedom from documented rhythm recurrence in paroxysmal AFib patients over 12 months [1] - Nearly 68% of patients with persistent AFib remained free from additional episodes after treatment with the Volt PFA System [1] - Patients reported significant improvements in quality-of-life scores, increasing from 63.6 to 91.4 for paroxysmal AFib patients and from 64.2 to 91.4 for persistent AFib patients [1] - The trial reported less than 6% of patients required repeat ablation, one of the lowest rates in the industry [1] - Physicians used an average of 4.6 therapy applications per vein, fewer than other competitive PFA systems [1] Group 2: TactiFlex Duo Ablation Catheter - The TactiFlex Duo Ablation Catheter demonstrated a clinically meaningful success rate of 81% for freedom from documented rhythm recurrence among paroxysmal AFib patients in the FOCALFLEX Global CE Mark trial [1] - Patient self-reported quality-of-life scores increased from 64.4 to 86.4 [1] - TactiFlex Duo is designed for focal ablation using a dual-energy platform, allowing tailored AFib therapy delivery [1] - The device received CE Mark approval, and the FDA granted Breakthrough Device Designation for treating Ventricular Tachycardia using PFA [1] Group 3: Market Position and Future Outlook - Abbott's Volt PFA System and TactiFlex Duo are positioned to empower physicians in treating a wide range of AFib cases, from newly diagnosed to complex cases [1] - The company aims to challenge the status quo in AFib treatment by developing better tools for physicians [1]